Israel-based IceCure Medical Ltd. (NASDAQ: ICCM) announced receiving patent authorization from the China National Intellectual Property Administration for its invention titled “Cryogenic System Connector.” This patent underscores the company’s commitment to advancing its minimally-invasive cryoablation technology.
Cryoablation Technology Innovation
IceCure’s technology focuses on destroying tumors through freezing, offering a less invasive alternative to surgical removal. The novel cryogenic pump, applicable in multiple clinical settings, is designed for use in multiple or extended procedures without the need to refill liquid nitrogen (LN2), enhancing efficiency and versatility in medical applications.-Fineline Info & Tech
Leave a Reply